CJC-1295 without Drug Affinity Complex (commonly designated CJC-1295 no DAC, or Mod GRF 1-29) is a synthetic modified analog of growth hormone-releasing hormone (GHRH) that has attracted considerable attention in peptide research. As a truncated and substituted form of endogenous GHRH, this compound serves as a valuable tool for investigating the somatotropic axis and the regulatory mechanisms governing pulsatile growth hormone secretion in preclinical models.
Structural Overview
CJC-1295 (no DAC) is a 30-amino-acid peptide derived from the first 29 residues of human growth hormone-releasing hormone, designated GRF(1-29), with an additional lysine residue and four key amino acid substitutions. The molecular weight of the compound is approximately 3,367 Da. The structural modifications were specifically engineered to address the primary limitation of native GHRH — its rapid enzymatic degradation in biological systems.
The four amino acid substitutions occur at positions 2, 8, 15, and 27 of the native GRF(1-29) sequence. At position 2, D-alanine replaces the native alanine, conferring resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage — the primary enzymatic pathway responsible for the extremely short half-life of endogenous GHRH, which is degraded within minutes in circulation. The substitution at position 8 (glutamine to asparagine) enhances receptor binding affinity, while modifications at positions 15 (glycine to alanine) and 27 (methionine to leucine) further improve metabolic stability by eliminating oxidation-prone residues and additional protease recognition sites.
These targeted modifications collectively extend the functional half-life of the peptide compared to native GRF(1-29) while preserving the core pharmacophore required for GHRH receptor engagement. The resulting compound maintains the bioactive conformation of the native hormone's N-terminal domain, which is essential for receptor recognition and activation.
GHRH Receptor Pharmacology
CJC-1295 (no DAC) exerts its primary activity through binding to the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells within the anterior pituitary gland. Class B GPCRs, also known as the secretin receptor family, are characterized by a large extracellular N-terminal domain that participates in initial ligand recognition, followed by engagement with the transmembrane domain to activate intracellular signaling.
Upon binding to the GHRHR, the peptide induces a conformational change in the receptor that facilitates coupling with the stimulatory G-alpha subunit (Gαs). This triggers activation of adenylyl cyclase, catalyzing the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The resulting elevation in intracellular cAMP activates protein kinase A (PKA), initiating a phosphorylation cascade that ultimately promotes the transcription, synthesis, and secretion of growth hormone from pituitary somatotrophs.
The cAMP/PKA signaling cascade activated by GHRHR engagement also modulates ion channel activity within somatotroph cells. PKA-mediated phosphorylation of voltage-gated calcium channels and potassium channels alters membrane excitability, facilitating the calcium influx necessary for the exocytotic release of GH-containing secretory granules. Research models have demonstrated that this signaling pathway operates with notable fidelity to the endogenous GHRH mechanism, suggesting that the structural modifications in CJC-1295 (no DAC) do not substantially alter downstream receptor pharmacology.
Pulsatile GH Release
A distinguishing feature of CJC-1295 (no DAC) in research models is its capacity to amplify the amplitude of growth hormone secretory pulses while preserving the physiological pulsatile pattern of GH release. Endogenous GH secretion follows an ultradian rhythm characterized by discrete secretory bursts interspersed with trough periods, a pattern governed by the alternating interplay between hypothalamic GHRH and somatostatin. This pulsatile pattern has been shown in preclinical studies to be functionally significant, as continuous GH exposure produces distinct downstream effects compared to intermittent exposure.
Due to its relatively shorter half-life compared to DAC-conjugated variants, CJC-1295 (no DAC) produces transient elevations in circulating GH that more closely mimic physiological secretory episodes. In preclinical models, administration has been observed to increase both the peak amplitude and the area under the curve (AUC) of individual GH pulses without eliminating the interpulse nadir — the low-GH trough period that appears to be critical for maintaining tissue sensitivity to GH signaling.
The preservation of feedback regulation is a notable characteristic observed in research settings. The hypothalamic-pituitary somatotropic axis employs multiple negative feedback loops, including GH-mediated stimulation of somatostatin release and IGF-1-mediated suppression of both GHRH and GH secretion. Studies in preclinical models suggest that CJC-1295 (no DAC) operates within these feedback constraints, meaning that the somatostatin counter-regulatory mechanism remains intact. This stands in contrast to continuous GHRH receptor stimulation, which has been observed to produce receptor desensitization and a blunting of the GH response over time.
IGF-1 Axis Effects
The downstream consequences of GH secretion amplified by CJC-1295 (no DAC) are mediated largely through the insulin-like growth factor 1 (IGF-1) axis. Growth hormone released from pituitary somatotrophs acts on hepatocytes via the GH receptor (GHR), a type I cytokine receptor that signals through the JAK2/STAT5 pathway. Activation of STAT5 transcription factors drives the hepatic production and secretion of IGF-1, which circulates bound to a family of IGF-binding proteins (IGFBPs), primarily IGFBP-3 in complex with the acid-labile subunit (ALS).
Preclinical investigations have observed that the pulsatile GH release pattern promoted by CJC-1295 (no DAC) produces corresponding modulation of circulating IGF-1 levels. The hepatic IGF-1 response integrates the cumulative GH signal, meaning that the pattern of GH exposure — not merely the total quantity — influences the magnitude and kinetics of IGF-1 production. Research models suggest that pulsatile GH input may be more efficient at driving IGF-1 synthesis than equivalent continuous GH exposure, potentially due to differences in GHR internalization and recycling dynamics.
IGF-1 itself acts through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates the PI3K/Akt and MAPK/ERK signaling cascades. These pathways mediate the anabolic and mitogenic effects historically attributed to growth hormone, including regulation of protein synthesis, cellular proliferation, and differentiation in various tissue types. In the context of the somatotropic axis, circulating IGF-1 also serves as a critical feedback signal, acting at both the hypothalamic and pituitary levels to modulate further GH secretion.
Distinction from the DAC Variant
The designation "no DAC" distinguishes this modified GRF(1-29) analog from the DAC-conjugated variant of CJC-1295, which incorporates a Drug Affinity Complex — a reactive moiety that forms a covalent bond with serum albumin following administration. This albumin conjugation dramatically extends the circulating half-life of the DAC variant, producing sustained and relatively continuous GHRH receptor stimulation over a period of days rather than the transient stimulation produced by the non-DAC form.
The pharmacokinetic distinction between these two forms carries significant implications for research design. The DAC variant produces prolonged elevation of both GH and IGF-1, effectively overriding the endogenous pulsatile pattern and creating a state of near-continuous somatotroph stimulation. In contrast, CJC-1295 (no DAC) produces a discrete pharmacological pulse that integrates with, rather than replaces, the endogenous secretory rhythm. Preclinical data suggest that this difference influences the pattern of downstream signaling, tissue responsiveness, and the integrity of feedback regulation.
From a research methodology perspective, the non-DAC variant offers advantages for studies investigating the acute dynamics of GHRH receptor signaling, pulsatile GH pharmacology, and the temporal relationships within the somatotropic axis. Its shorter duration of action allows researchers to examine time-resolved responses and to combine it with other secretagogues in controlled experimental paradigms without the confounding variable of persistent receptor occupancy.
Current Research Landscape
The modified GRF(1-29) analog continues to serve as an important tool in neuroendocrine research, particularly in studies examining the regulation of the somatotropic axis and the physiological significance of GH pulsatility. Ongoing preclinical investigations are exploring the peptide's utility in combination protocols with growth hormone secretagogues (GHS) that act through complementary receptor pathways, examining whether synergistic amplification of GH output can be achieved while maintaining physiological release dynamics.
Areas of active investigation include the compound's effects on somatotroph gene expression, its interactions with somatostatin receptor subtypes, and the downstream metabolic consequences of GHRH-driven GH pulsatility in various tissue models. Additionally, researchers continue to examine the structure-activity relationships of the four amino acid substitutions, seeking to further optimize metabolic stability without compromising receptor selectivity or binding affinity.
It is important for the research community to note that the majority of available data on CJC-1295 (no DAC) derives from preclinical and in-vitro model systems. As with all research peptides, findings in these controlled environments require cautious interpretation and should not be extrapolated beyond the scope of the experimental conditions in which they were generated.